Exelixis, Inc. announced that the U.S. Food and Drug Administration has accepted its New Drug Application for the combination of zanzalintinib and atezolizumab in adult patients with metastatic colorectal cancer who have progressed after standard chemotherapy and, for RAS wild‑type patients, prior anti‑EGFR therapy. The acceptance, dated February 2 2026, marks a key regulatory milestone that moves the drug closer to potential approval.
Zanzalintinib is an oral kinase inhibitor that targets TAM kinases, MET, and VEGF receptors, pathways that drive tumor growth and metastasis. When paired with the immune checkpoint inhibitor atezolizumab, the combination is designed to attack colorectal tumors from multiple angles, offering a novel therapeutic option for a heavily pre‑treated patient population.
The approval decision is based on the phase 3 STELLAR‑303 trial, which enrolled 901 patients and evaluated overall survival as a primary endpoint. The study demonstrated a statistically significant improvement in overall survival versus regorafenib in the intention‑to‑treat population, with a median survival benefit that exceeded the threshold set by the FDA. Data for the subgroup of patients without active liver metastases were still immature at the time of the acceptance.
For Exelixis, the FDA acceptance represents a strategic pivot toward a multi‑product oncology portfolio. The company’s flagship drug, cabozantinib, faces generic competition expected to enter the market around 2030‑2031, and the new combination offers a potential revenue stream that could offset the impending loss of exclusivity. By advancing a first‑in‑class oral kinase inhibitor in combination with an immune checkpoint inhibitor, Exelixis is positioning itself to capture a share of the growing metastatic colorectal cancer market, which is projected to see 159,000 new cases in the United States in 2026, with roughly a quarter diagnosed at the metastatic stage.
Dana T. Aftab, Ph.D., Executive Vice President of Research and Development, said the FDA acceptance "underscores the clinical value of our approach and brings us one step closer to delivering a new treatment option for patients with limited choices." She added that the company remains focused on accelerating the development of its pipeline while managing the transition toward the cabozantinib patent cliff.
The acceptance sets a Prescription Drug User Fee Act target action date of December 3 2026, giving Exelixis a clear timeline for the next regulatory milestone. The company’s management has indicated confidence in meeting this schedule, citing robust trial data and a well‑structured development plan.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.